PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback